SURF Insider Trading Activity and SEC Form 4 Filings
SURF insider trading summary
No open-market insider purchases or sales of Surface Oncology, Inc. (SURF) have been reported on SEC Form 4 in the past 12 months.
Latest SURF insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 1, 2023 | Robert W. Ross | Chief Executive Officer | Sell | $16K (16,713 @ $0.94) |
| Aug 1, 2023 | Chandra Adams | Deputy GC | Sell | $4K (3,901 @ $0.94) |
| Aug 1, 2023 | Jessica Fees | Chief Financial Officer | Sell | $9K (9,434 @ $0.94) |
| Aug 1, 2023 | Alison Oneill | Chief Medical Officer | Sell | $7K (7,042 @ $0.94) |
| Aug 3, 2022 | Vito J. Palombella | Chief Scientific Officer | Sell | $8K (4,463 @ $1.72) |
| Aug 3, 2022 | Jessica Fees | Chief Financial Officer | Sell | $10K (5,980 @ $1.72) |
| Aug 3, 2022 | Robert W. Ross | Chief Executive Officer | Sell | $18K (10,594 @ $1.72) |
| Aug 3, 2022 | Henry C. Rath | Chief Business Officer | Sell | $10K (5,676 @ $1.72) |
| Aug 3, 2022 | Alison Oneill | Chief Medical Officer | Sell | $8K (4,463 @ $1.72) |
| Jul 21, 2021 | Alison Oneill | Chief Medical Officer | Sell | $90K (14,809 @ $6.10) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.